文献速递慢性肾脏病血液净化与透析

罗沙司他治疗慢性肾脏病贫血的疗效与安全性:一项荟萃分析

The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

该荟萃分析纳入4项2期和2项3期随机对照试验共1010例慢性肾脏病患者,比较罗沙司他与安慰剂或阿法依泊汀治疗贫血的疗效与安全性。结果显示罗沙司他可显著升高血红蛋白和转铁蛋白水平、降低铁调素,但不良事件发生率在罗沙司他组高于阿法依泊汀组,严重不良事件风险未见显著增加。

要点

  • 罗沙司他可有效升高非透析依赖患者血红蛋白并维持透析依赖患者血红蛋白。
  • 罗沙司他组不良事件发生率显著高于阿法依泊汀组(RR 1.25,P=0.04)。
  • 短期使用罗沙司他未观察到严重不良事件风险显著增加。

核心结论

  • 口服罗沙司他可有效升高非透析依赖慢性肾脏病患者的血红蛋白水平,并有效维持透析依赖患者的血红蛋白水平。
  • 短期使用罗沙司他未观察到严重不良事件风险增加,但不良事件发生率高于阿法依泊汀。

研究设计与样本

  • 荟萃分析,系统检索八个电子资源数据库的随机对照试验。
  • 纳入4项2期和2项3期研究,共1010例参与者。

主要发现

  • 与安慰剂相比,罗沙司他组血红蛋白显著升高(SMD 1.57,95%CI 1.17-1.98,低质量证据)。
  • 与安慰剂相比,罗沙司他组转铁蛋白显著升高(SMD 1.81,95%CI 1.53-2.08,低质量证据)。
  • 与阿法依泊汀相比,罗沙司他组血红蛋白显著升高(SMD 0.47,95%CI 0.02-0.93,极低质量证据)。
  • 与阿法依泊汀相比,罗沙司他组转铁蛋白显著升高(SMD 1.05,95%CI 0.81-1.29,低质量证据)。
  • 罗沙司他组铁调素较安慰剂组显著降低(SMD -1.72,95%CI -3.03至-0.41,极低质量证据),较阿法依泊汀组亦显著降低(SMD -0.23,95%CI -0.43至-0.02,低质量证据)。

关键数值与推荐

  • 罗沙司他组铁蛋白和转铁蛋白饱和度较安慰剂组显著降低(SMD -0.82,95%CI -1.31至-0.33;SMD -0.54,95%CI -0.76至-0.32,均低质量证据)。
  • 罗沙司他组铁蛋白和转铁蛋白饱和度与阿法依泊汀组相当(SMD 0.02,95%CI -0.18至0.21;SMD 0.15,95%CI -0.04至0.35,均低质量证据)。
  • 罗沙司他组不良事件发生率与安慰剂组无显著差异(RR 0.99,95%CI 0.83-1.18,P=0.89,极低质量证据)。
  • 罗沙司他组不良事件发生率显著高于阿法依泊汀组(RR 1.25,95%CI 1.01-1.54,P=0.04,低质量证据)。
  • 非透析依赖和透析依赖患者中,罗沙司他与严重不良事件发生率无显著关联(RR 1.08,95%CI 0.51-2.28;RR 1.43,95%CI 0.85-2.40,均极低质量证据)。

临床怎么用

  • 罗沙司他可考虑用于慢性肾脏病贫血患者,尤其是非透析依赖患者升高血红蛋白及透析依赖患者维持血红蛋白。
  • 使用罗沙司他时应关注不良事件发生风险,尤其与阿法依泊汀相比时。
  • 短期使用罗沙司他时严重不良事件风险未见显著增加,但仍需长期监测。

局限性

  • 纳入研究数量有限(4项2期和2项3期),总样本量1010例。
  • 多数结局证据质量低或极低。
  • 罗沙司他与阿法依泊汀的比较仅涉及透析依赖患者,与安慰剂的比较仅涉及非透析依赖患者。
  • 随访时间可能较短,无法评估长期安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease (CKD) is an increasing public health issue. Anemia, which is a complication of CKD, is associated with reduced quality of life and increased morbidity and mortality. Currently quite a few clinical studies have been conducted to compare roxadustat with epoetin alfa [all for dialysis-dependent (DD) patients] or placebo [all for nondialysis-dependent (NDD) patients]. Our meta-analysis aimed to investigate the efficacy and safety of roxadustat for anemia in patients with CKD. METHODS: We thoroughly searched eight electronic resource databases for randomized controlled trials (RCTs) comparing the efficacy and safety between roxadustat versus epoetin alfa or placebo for the treatment of anemia in patients with CKD. RESULTS: Four Phase 2 and two Phase 3 studies with 1010 participants were included. Hemoglobin (Hb) and transferrin levels were increased significantly in the roxadustat group versus those in the placebo {standard mean difference [SMD] 1.57 [95% confidence interval (CI) 1.17-1.98]; SMD 1.81 [95% CI 1.53-2.08]; respectively, both low-quality evidence} or epoetin alfa group [SMD 0.47 (95% CI 0.02-0.93), very low-quality evidence; SMD 1.05 (95% CI 0.81-1.29), low-quality evidence; respectively]. Hepcidin levels were reduced significantly in the roxadustat group versus those in the placebo [SMD -1.72 (95% CI -3.03 to -0.41), very low-quality evidence] or epoetin alfa group [SMD -0.23 (95% CI -0.43 to -0.02), low-quality evidence]. Ferritin and serum transferrin saturation (TSAT) levels were reduced significantly in the roxadustat group versus those in the placebo group [SMD -0.82 (95% CI -1.31 to -0.33); SMD -0.54 (95% CI -0.76 to -0.32), respectively; both low-quality evidence] and ferritin and TSAT levels in the roxadustat group were comparable to those in the epoetin alfa group [SMD 0.02 (95% CI -0.18-0.21); SMD 0.15 (95% CI -0.04-0.35), respectively, both low-quality evidence]. As for safety, the incidence of adverse events (AEs) in the roxadustat group was insignificantly different from that of the placebo group [risk ratio (RR) 0.99 (95% CI 0.83-1.18); P = 0.89, very low-quality evidence]. But the incidence of AEs in the roxadustat group was significantly higher than that in the epoetin alfa group [RR 1.25 (95% CI 1.01-1.54); P = 0.04, low-quality evidence]. There was no significant association between roxadustat and the incidence of serious AEs (SAEs) for both NDD and DD patients [RR 1.08 (95% CI 0.51-2.28) and RR 1.43 (95% CI 0.85-2.40), respectively, both very low-quality evidence]. CONCLUSION: In this meta-analysis of RCTs, we found evidence that after the oral administration of roxadustat, NDD patients' Hb levels were increased effectively and DD patients' Hb levels were maintained effectively. The risk of SAEs was not observed with the short-term use of roxadustat. These findings support roxadustat for the treatment of anemia in patients with CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zheng Q, Yang H, Fu X, et al. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2021. PMID: 33051677. doi:10.1093/ndt/gfaa110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。